<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02236078</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-6435</org_study_id>
    <nct_id>NCT02236078</nct_id>
  </id_info>
  <brief_title>Brief Bactericidal Activity of Anti-Tuberculosis Drugs</brief_title>
  <acronym>BBA</acronym>
  <official_title>Brief Bactericidal Activity of Anti-Tuberculosis Drugs in Drug-Resistant Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will determine the bactericidal activity of high-dose isoniazid against M.&#xD;
      tuberculosis isolates that are (1) susceptible to isoniazid at 2.0 mcg/ml but resistant at&#xD;
      0.1 and 0.4 mcg/ml or (2) susceptible at 0.4 mcg/ml but resistant at 0.1 mcg/ml when tested&#xD;
      in the BD MGIT 960 system. Further, the investigators will investigate the molecular genetic&#xD;
      determinants of these differences in susceptibility.&#xD;
&#xD;
      To achieve these objectives the investigators will carry out an innovative variation on early&#xD;
      bactericidal activity (EBA) study methodology. Patients at risk for drug-resistant TB will be&#xD;
      screened for INH resistance using approved molecular assays. In those with INH-resistant TB,&#xD;
      the investigators will quickly perform phenotypic DSTs using the direct method in the Bactec&#xD;
      Mycobacterium Growth Indicator Tube (MGIT) 960 system, so results will be available within 7&#xD;
      days. If the DST results show the susceptibility patterns noted above, patients will receive&#xD;
      900 mg/d INH (600 mg if &lt;45kg), and assess its effect with serial quantitative sputum&#xD;
      cultures for 6 days. If the concentration of viable bacteria decreases significantly, the&#xD;
      investigators will interpret this to mean the drug is having an effect. If not, the drug is&#xD;
      ineffective. After 6 days, the patients will resume treatment according to national&#xD;
      guidelines.&#xD;
&#xD;
      In case the investigators identify drugs that are effective under these conditions, the&#xD;
      investigators will sequence known and putative genes associated with the action of these&#xD;
      drugs for the mycobacterial isolates from these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delta CFU/ml/day</measure>
    <time_frame>6 days</time_frame>
    <description>Change in colony forming units per ml of sputum over 6 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-detection (TTD)</measure>
    <time_frame>6 days</time_frame>
    <description>Interval in hours from culture inoculation to detection of mycobacterial growth in MGIT 960</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acquired isoniazid resistance</measure>
    <time_frame>2 months</time_frame>
    <description>Increased level of resistance to isoniazid</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Drug-resistant Tuberculosis</condition>
  <condition>Isoniazid Resistant Tuberculosis (Disorder)</condition>
  <arm_group>
    <arm_group_label>High dose isoniazid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing &lt;45 kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose isoniazid</intervention_name>
    <description>See arm description</description>
    <arm_group_label>High dose isoniazid</arm_group_label>
    <other_name>High dose INH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  INH resistance by approved molecular genetic test&#xD;
&#xD;
          -  Phenotypic drug susceptibility test results match one of the required patterns&#xD;
&#xD;
          -  Sputum microscopy positive for acid fast bacilli&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ineligible for MDR TB treatment according to national guidelines&#xD;
&#xD;
          -  HIV infection with CD4 count less than 50&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Incarceration&#xD;
&#xD;
          -  Too sick to participate (Karnofsky score &lt;60, arterial pO2&lt;90, respiratory rate&#xD;
             repeatedly &gt;25/min, clinician's judgment)&#xD;
&#xD;
          -  Hepatic enzymes &gt;3x normal&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt;60 mL/min/1.73 m2&#xD;
&#xD;
          -  Unable to provide adequate sputum specimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah E. Smith-Jeffcoat, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.S. Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. P. Cegielski, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>JP Cegielski Consulting LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute for Research on Tuberculosis</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <removed_countries>
    <country>Kenya</country>
  </removed_countries>
  <reference>
    <citation>Dalton T, Cegielski P, Akksilp S, Asencios L, Campos Caoili J, Cho SN, Erokhin VV, Ershova J, Gler MT, Kazennyy BY, Kim HJ, Kliiman K, Kurbatova E, Kvasnovsky C, Leimane V, van der Walt M, Via LE, Volchenkov GV, Yagui MA, Kang H; Global PETTS Investigators, Akksilp R, Sitti W, Wattanaamornkiet W, Andreevskaya SN, Chernousova LN, Demikhova OV, Larionova EE, Smirnova TG, Vasilieva IA, Vorobyeva AV, Barry CE 3rd, Cai Y, Shamputa IC, Bayona J, Contreras C, Bonilla C, Jave O, Brand J, Lancaster J, Odendaal R, Chen MP, Diem L, Metchock B, Tan K, Taylor A, Wolfgang M, Cho E, Eum SY, Kwak HK, Lee J, Lee J, Min S, Degtyareva I, Nemtsova ES, Khorosheva T, Kyryanova EV, Egos G, Perez MT, Tupasi T, Hwang SH, Kim CK, Kim SY, Lee HJ, Kuksa L, Norvaisha I, Skenders G, Sture I, Kummik T, Kuznetsova T, Somova T, Levina K, Pariona G, Yale G, Suarez C, Valencia E, Viiklepp P. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012 Oct 20;380(9851):1406-17. doi: 10.1016/S0140-6736(12)60734-X. Epub 2012 Aug 30. Erratum in: Lancet. 2012 Oct 20;380(9851):1386.</citation>
    <PMID>22938757</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2014</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

